Effect of anti-IL-17 on airway responsiveness in asthma patients
The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance: a Longitudinal Cohort Study
This study is testing if a new treatment for certain skin and joint conditions can also help adults with severe asthma breathe better by reducing their airway sensitivity.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 74 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Copenhagen University Hospital, Hvidovre Academic / other |
| Locations | 1 site (Hvidovre, Capital Region) |
| Trial ID | NCT06224634 on ClinicalTrials.gov |
What this trial studies
This observational longitudinal cohort study evaluates how monoclonal antibodies targeting interleukin 17 (anti-IL-17) influence airway hyperreactivity and resistance in adults with dermatological or rheumatological conditions. Participants planning to start anti-IL-17 treatment will undergo assessments of airway responsiveness using methacholine challenges and spirometry to measure changes in lung function. The study aims to determine if anti-IL-17 can effectively reduce airway hyperreactivity, particularly in patients with severe non-Type 2 asthma. This research is significant as it explores a novel treatment avenue for asthma patients who have not responded well to conventional therapies.
Who should consider this trial
Good fit: Ideal candidates are adults with dermatological or rheumatological conditions who are about to begin treatment with anti-IL-17 antibodies.
Not a fit: Patients with uncontrolled hypertension, recent myocardial infarction or stroke, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option for asthma patients, particularly those with severe non-Type 2 asthma, improving their respiratory function and quality of life.
How similar studies have performed: While previous studies have explored IL-17's role in asthma, none have specifically investigated the impact of anti-IL-17 treatment on airway hyperresponsiveness, making this approach novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients planning to start treatment with anti-IL-17 antibodies Exclusion Criteria: * Current pregnancy * FEV1 \< 1.5L or less than 60% of predicted value expected. * Previous anaphylactic shock or severe allergic reaction to medicine * Uncontrolled hypertension * Myocardial infarction or stroke within the last 3 months * Known aortic aneurysm * Recent eye surgery or risk of elevated intracranial pressure * Treatment with systemic corticosteroids within 6 weeks
Where this trial is running
Hvidovre, Capital Region
- Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital — Hvidovre, Capital Region, Denmark (Recruiting)
Study contacts
- Principal investigator: Jonas A Baekdal, MD — University hospital, Hvidovre
- Study coordinator: Jonas A Baekdal, MD
- Email: jonas.aggerholm.baekdal.02@regionh.dk
- Phone: +45 60134687
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.